Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EBIT (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Orix | 44.91 Bn | 45.24 Bn | 4.68 Bn |
| 2 | Royalty Pharma | 36.78 Bn | 38.89 Bn | - |
| 3 | Royal Gold | 22.19 Bn | 22.06 Bn | 390.45 Mn |
| 4 | OR Royalties | 6.98 Bn | 6.91 Bn | 82.22 Mn |
| 5 | Encore Capital | 2.06 Bn | 1.88 Bn | 455.04 Mn |
| 6 | Atlanticus Holdings | 1.41 Bn | 853.17 Mn | 686.46 Mn |
| 7 | Jefferson Capital | 1.23 Bn | 1.21 Bn | - |
| 8 | Upbound | 1.11 Bn | 1.00 Bn | 594.84 Mn |
| 9 | Lufax Holding | 1.08 Bn | -1.19 Bn | - |
| 10 | Metalla Royalty & Streaming | 957.79 Mn | 946.72 Mn | 4.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -76.36% |
| Mar 31, 2026 | 44.97% |
| Dec 31, 2025 | -9.08% |
| Sep 30, 2025 | 103.60% |
| Jun 30, 2025 | -60.73% |
| Mar 31, 2025 | 47.76% |
| Dec 31, 2024 | -50.82% |
| Sep 30, 2024 | 172.62% |
| Jun 30, 2024 | 465.48% |
| Mar 31, 2024 | -112.04% |
| Dec 31, 2023 | 304.71% |
| Sep 30, 2023 | -39.14% |
| Jun 30, 2023 | -48.05% |
| Mar 31, 2023 | 199.24% |
| Dec 31, 2022 | -351.11% |
| Sep 30, 2022 | -49.12% |
| Jun 30, 2022 | 71.94% |
| Mar 31, 2022 | 43.22% |
| Dec 31, 2021 | -49.38% |
| Sep 30, 2021 | -59.32% |